A multi-centre, randomised, controlled trial of bronchoalveolar lavage (BAL) directed therapy in young children with cystic fibrosis (CF).
Completed
- Conditions
- Cystic FibrosisHuman Genetics and Inherited Disorders - Cystic fibrosis
- Registration Number
- ACTRN12605000665639
- Lead Sponsor
- HMRC
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 165
Inclusion Criteria
All infants diagnosed with cystic fibrosis through the neonatal screening program in Queensland, New South Wales, South Australia, Victoria, Auckland and North Auckland Infants diagnosed with meconium ileus may be enrolled when diagnosis of cystic fibrosis is confirmed. A diagnosis of cystic fibrosis must be confirmed with a positive sweat chloride (Gibson Cooke with a chloride > 60mmol/l).Informed consent from parents or guardians.
Exclusion Criteria
Informed consent cannot be obtained. Infant is severely ill at the time of diagnosis and requires ventilatory support. Family are planning to move overseas in the next few years.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method